Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | F13A1 | P00488 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | TGM1 | P22735 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6777638 | 1.00 | CCNC (0.48) | CCNCCDK8MAPTF13A1TGM2 | |
| SCHEMBL8422669 | 0.86 | GPR52 (0.51) | CCNCCDK8MAPTCYP1A2CYP2A6 | |
| SCHEMBL8422670 | 0.86 | GPR52 (0.51) | CCNCCDK8MAPTCYP1A2CYP2A6 | |
| SCHEMBL14349796 | 0.85 | KMT2A (0.45) | CCNCCDK8MAPTCYP1A2CYP2A6 | |
| SCHEMBL6263496 | 0.82 | MAPT (0.57) | MAPTF13A1TGM2TGM1TTR | |
| SCHEMBL6263498 | 0.82 | MAPT (0.57) | MAPTF13A1TGM2TGM1TTR | |
| SCHEMBL933767 | 0.79 | MAPT (0.51) | MAPTF13A1TGM2TGM1TTR | |
| SCHEMBL933766 | 0.79 | MAPT (0.51) | MAPTF13A1TGM2TGM1TTR | |
| SCHEMBL6214767 | 0.79 | TBXA2R (0.56) | CYP1A2CYP2A6 | |
| SCHEMBL6214765 | 0.79 | TBXA2R (0.56) | CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747032-B2 | DOUBLE ALPHA 2/5-HT 2C ANTAGONISTS USED TO TREAT DEPRESSION, IMPULSIVE BEHAVIOUR DISORDERS, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, COGNITIVE DISORDERS AND DISORDERS INVOLVING SEXUAL FUNCTION, SLEEP AND EATING | LES LABORATOIRES SERVIER (FR) | 2004-06-08 | — | — | US | disclosed |
| US-20030087916-A1 | Pyrimidin-4-one compounds | LES LABORATOIRES SERVIER (FR) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087916-A1 | Pyrimidin-4-one compounds | HTR2C, HTR1A, HTR4 | CCNC 487/4885CDK8 959/4885MAPT 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.